MindImmune Therapeutics: Valuation, Funding & Investors
MindImmune Therapeutics is a venture-backed biotechnology company developing products that target the immunological drivers of neurodegenerative disease. Its lead program, MITI-101, is designed to block the harmful recruitment of peripheral immune cells into the brain in patients with Alzheimer’s disease and other neurodegenerative conditions.
Leadership & Board
- Current Number of Employees
- 15
- Current LinkedIn Followers
- 1,913
Latest Estimated Valuation
- Total Amount Raised
- $10M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $10M
- Latest Funding Round
- Series A
Employee Trend
MindImmune Therapeutics had 15 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
15Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
MindImmune Therapeutics had 1,913 followers as of October 26, 2026. The number of followers increased by 5 (0.26%) week-over-week.
1,913Latest Followers Count
5(0.26%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 24, 2025 | Series A | $10.20M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Gates Frontier | Series A |
| Dolby Family Ventures | Series A |
| Pfizer Ventures | Series A |
| Slater Technology Fund | Series A |
| RightHill Ventures | Series A |
| Foundation for a Better World | Series A |
Similar Companies
A snapshot of private companies similar to MindImmune Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
